|
gptkbp:instance_of
|
gptkb:drug
|
|
gptkbp:bfsLayer
|
3
|
|
gptkbp:bfsParent
|
gptkb:Eli_Lilly_and_Company
|
|
gptkbp:approves
|
gptkb:FDA
|
|
gptkbp:brand
|
gptkb:Cymbalta
gptkb:Duloxetine_hydrochloride
Yentreve
|
|
gptkbp:category
|
gptkb:C
|
|
gptkbp:clinical_trial
|
Phase III
|
|
gptkbp:contraindication
|
MAO inhibitors
severe liver disease
uncontrolled narrow-angle glaucoma
|
|
gptkbp:discontinued
|
gptkb:none
|
|
gptkbp:dosage_form
|
30 mg
120 mg
60 mg
|
|
gptkbp:duration
|
varies
|
|
gptkbp:effective_date
|
2004-08-03
|
|
gptkbp:excretion
|
urine
|
|
gptkbp:formulation
|
gptkb:beer
delayed-release capsule
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Cymbalta
|
|
gptkbp:ingredients
|
gptkb:duloxetine
|
|
gptkbp:interacts_with
|
gptkb:warfarin
NSAI Ds
other serotonergic drugs
|
|
gptkbp:is_atype_of
|
N06 A X21
|
|
gptkbp:is_used_for
|
chronic pain
fibromyalgia
generalized anxiety disorder
major depressive disorder
|
|
gptkbp:legal_issue
|
prescription only
|
|
gptkbp:lifespan
|
12 hours
|
|
gptkbp:manager
|
oral
|
|
gptkbp:manufacturer
|
gptkb:Eli_Lilly_and_Company
|
|
gptkbp:marketed_as
|
gptkb:legislation
gptkb:Australia
gptkb:United_States
gptkb:Native_American_tribe
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:side_effect
|
dizziness
fatigue
nausea
insomnia
constipation
dry mouth
sweating
|
|
gptkbp:symptoms
|
possible
|
|
gptkbp:type
|
gptkb:drug
|
|
gptkbp:type_of_care
|
important
|